Amgen Inc.'s (AMGN) proposed $130-a-share, or $9.5 billion,
takeover of Onyx Pharmaceuticals Inc. (ONXX) has stalled over
access to drug trial data, although the offer price itself is not
at issue, Bloomberg News reported Thursday on its website, citing
three people familiar with the matter.
The deal is being slowed over whether Onyx will provide to Amgen
data on a blood-cancer treatment which is in the midst of a trial.
Because the trial is ongoing, Onyx doesn't have access to the data
and obtaining the results prior to conclusion of the study could
slow the drug's approval, one person told Bloomberg.
A spokeswoman for Onyx declined comment to Bloomberg and a
spokeswoman for Amgen said the company doesn't comment on market
rumors.
Full story at:
www.bloomberg.com/news/2013-08-15/amgen-talks-to-buy-onyx-said-to-stall-on-drug-trial-data.html
Write to nymonitoring@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires